



This document summarizes the new or refined processes for hospitals and health care facilities to request critical resources for COVID-19 response. For questions, please contact [Jackie Gatz](#) at 573-893-3700, ext. 1330.



## 1. PERSONAL PROTECTIVE EQUIPMENT

- Health care facilities should continue to place routine orders with their primary PPE supply vendors to maintain the established supply chain and receive allocations from these vendors as the supply chain recovers. The State of Missouri has established three primary resources to assist health care facilities with sourcing PPE.
- **PPE Marketplace**
  - The State of Missouri [platform](#) is designed to match health care providers with suppliers of PPE and other medical supplies to respond to COVID-19. Currently, there are 347 validated vendors registered in the system, providing 29 unique PPE products.
- **State or Federally Sourced PPE Reserves**
  - Missouri has limited PPE reserves to assist in filling critical needs and will prioritize health care providers providing direct care to confirmed or suspected COVID-19 patients. Hospitals and health care providers must complete and submit an online [PPE order form](#).
- **Battelle N95 Decontamination System**
  - The FDA-approved [Battelle Decontamination System](#) for use in decontaminating compatible N95 or N95-equivalent respirators for reuse by health care personnel is fully operational and located in Jefferson City. MHA published a [guide](#), which includes the drop-off and pick-up locations throughout the state, as well as contact information for each location.

## 2. TESTING SUPPLIES

- The Missouri Department of Health and Senior Services State Public Health Laboratory initiated a [new online order system](#) to request COVID-19 specimen collection supplies. **The requesting organization may request swabs and viral media (Viral Transport Media, Saline, Universal Transport Media) when their current demand exceeds available resources from their primary and secondary vendors.** Please complete the request form in its entirety, including shipping address, as failure to do so may result in shipping delays.



### 3. REMDESIVIR

- Remdesivir, a product of Gilead Sciences, Inc., has demonstrated early promise in clinical trials to treat acutely ill patients with COVID-19. Since mid-May, Missouri has [received](#) shipments of remdesivir from the U.S. Department of Health and Human Services to be administered to hospitalized patients diagnosed with COVID-19. The first round of the limited supply was allocated and distributed to hospitals with ventilated COVID-19 patients. Additional shipments of larger quantities allow for broader distribution to any hospital with a hospitalized COVID-19 patient who meet the U.S. Food and Drug Administration's inclusion criteria and may benefit from medication treatment. Remdesivir is administered to patients in accordance with the Scope of Authorization and all additional requirements included in the FDA's [EUA](#) issued to Gilead Sciences, Inc., on May 1, 2020, and the corresponding [Fact Sheet for Health Care Providers](#).
- To facilitate distribution, MHA requested all Missouri hospitals interested in receiving remdesivir sign an evergreen attestation. The purpose of the attestation is to affirm that, in the event the hospital or health system meets allocation criteria at any time the state receives a shipment, it desires to be a candidate for distribution of the drug. On each day that a shipment arrives to Missouri, MHA provides DHSS with the list of hospitals that have signed the attestation and the most current hospitalization data from NHSN to inform allocation and distribution.
- If a hospital or health system receives a supply of remdesivir and does not have a patient or patients for whom administration is clinically indicated, the hospital or health system may store the remdesivir for no more than 30 days, after which time the hospital/health system agrees to contact the Emergency Response Center at 800-392-0272 to arrange for DHSS to reallocate the supply.
- DHSS will, at its discretion, maintain a reserve of remdesivir in Jefferson City, pending shelf life and availability. Hospitals may request remdesivir directly through the Emergency Response Center at 800-392-0272.